Does derived neutrophil-to-lymphocyte ratio predict no-reflow in patients with ST-elevation myocardial infarction?
Derived neutrophil-to-lymphocyte ratio is a simple and cost-effective marker that may predict no-reflow risk in STEMI patients.
dNLR is a simple, cost-effective marker that may help identify patients at high risk of no-reflow in STEMI. Further prospective studies are warranted.
Taş et al. (Sun,) studied this question.